Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV-T in HPV-16 Positive Solid Tumors
NCT05895370Phase 1Unknown
- Sponsor
- BGI
- Start
- Apr 2023
- Primary completion
- Dec 2024
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HPV-T in solid tumor, sponsored by BGI. Primary endpoint: Number of participants with adverse events as assessed by CTCAE v5.0 up to 24 months. Status: unknown.
02
Drugs
HPV-T
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05895370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05895370.